Delivering therapeutics to the brain to treat Parkinson's Disease (PD) is severely limited by a complex series of physiological and biochemical hurdles. While systemic drug levels may be adequate, the true brain bioavailability—the fraction of the drug that successfully crosses into the brain parenchyma to reach dopaminergic neurons—remains critically low.

​

Extensive First-Pass Metabolism: Oral therapies are aggressively metabolized in the gastrointestinal tract and liver. For instance, without peripheral inhibitors like carbidopa, the gold-standard drug Levodopa (L-DOPA) is rapidly converted to dopamine in the periphery, leaving less than 1% to reach the brain.

Transporter Competition: L-DOPA relies on the Large Neutral Amino Acid Transporter 1 (LAT1) to cross the BBB. This creates a highly saturable process where dietary proteins and amino acids directly compete with the drug, leading to unpredictable brain concentrations and the clinical "on-off" motor phenomena.

.Gastrointestinal Dysmotility: PD patients frequently suffer from gastroparesis, erratic gastric emptying, and gut dysbiosis. This slows down and disrupts the absorption window of oral medications well before they reach systemic blood circulation.